Every S-1 that PMGC Holdings Inc. (ELAB) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-1 covers the registration statement a company files to sell shares publicly, so if you follow ELAB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ELAB filings page.
PMGC Holdings Inc. (ELAB) is registering up to 5,000,000 shares of common stock for resale by existing investors under a Form S-1/A. The shares include 56,700 commitment shares, 10,300 pre-delivery shares, and up to 4,933,000 additional shares issuable to Streeterville Capital under a secured pre-paid equity purchase facility.
The company is not selling shares in this prospectus and will not receive proceeds from resales, although it has already received net proceeds of $3,990,000 from an initial $5,000,000 pre-paid purchase and may receive up to $20 million in aggregate under the equity facility. ELAB recently increased its authorized common stock to 2,000,000,000 shares and effected a 1-for-3.5 reverse stock split. Its strategy centers on acquiring operating businesses and advancing biotechnology assets, including probiotic candidates EL-22 and EL-32 for muscle preservation in obesity treatment, while managing substantial going-concern and loss history risks.
PMGC Holdings Inc. is registering 236,543 shares of common stock for resale, all issuable upon exercise of outstanding warrants held by selling shareholders. The company is not selling any shares in this offering and will only receive cash if the warrants are exercised, which would total approximately $1.56 million if all are exercised for cash. The warrants have an exercise price of $6.615 per share, become exercisable after shareholder approval, remain outstanding for five years, and are subject to a 9.99% beneficial ownership cap.
PMGC has transformed into a diversified holding company with biotechnology (NorthStrive Biosciences), precision manufacturing (AGA Precision Systems and Pacific Sun Packaging), and investment operations (PMGC Capital). It recently divested its prior Elevai Skincare business to focus on larger-market biotech assets such as EL‑22 and EL‑32. The company faces substantial doubt about its ability to continue as a going concern, with an accumulated deficit of $18,034,757 as of September 30, 2025 and continued losses.
To fund operations and acquisitions, PMGC entered into a secured equity line facility providing up to $20,000,000 in pre‑paid share purchases, received net proceeds of $3,990,000 from an initial $5,000,000 pre‑paid purchase, and raised $1,668,218.50 via warrant inducement transactions. It also increased authorized common stock from 81,632,654 to 2,000,000,000, reserved 8,000,000 shares for the equity facility, and completed cash acquisitions of AGA Precision Systems for $650,000 and Pacific Sun Packaging for $1,148,000 plus an earnout. As of the date of the prospectus, 744,121 shares of common stock are outstanding, which would rise to 980,664 shares if all registered warrant shares are issued.
PMGC Holdings Inc. (Nasdaq: ELAB) filed a Form S-1 to register up to 5,000,000 shares of common stock for resale by selling security holders, including 56,700 commitment shares, 10,300 pre-delivery shares, and up to 4,933,000 shares issuable to Streeterville under pre-paid purchases. The company is not selling shares in this offering and will not receive proceeds from sales by the selling holders.
PMGC notes a separate equity purchase facility under which the maximum gross proceeds are $20,000,000. The Initial Pre-Paid Purchase of $5,000,000 closed on September 26, 2025, yielding $3,990,000 in net proceeds after fees. The filing highlights potential dilution from future issuances tied to the Purchase Agreement and caps Streeterville’s ownership at 9.99% per the Maximum Percentage provision.
Shares outstanding were 744,121 before this offering, and the table shows 5,677,121 after. ELAB last closed at $9.03 on October 14, 2025. The company discloses a going concern uncertainty and recently increased authorized common stock to 2,000,000,000, with an 8,000,000 share reserve for the facility.
PMGC Holdings Inc. (Nasdaq: ELAB) filed Amendment No. 1 to a Form S-1 to register up to 236,543 shares of common stock for resale by selling shareholders. These shares are issuable upon exercise of previously issued warrants. The company is not selling any shares in this registration and will not receive proceeds from any resale by the holders. PMGC states it could receive approximately $1.56 million only if all warrants are exercised for cash.
The warrants have an exercise price of $6.615 per share, become exercisable on or after the Shareholder Approval Date, and expire five years after that date, subject to a 9.99% (or 4.99%) beneficial ownership cap. A reverse stock split of 1:3.5 was effected on September 2, 2025. The company discloses substantial doubt about its ability to continue as a going concern as of December 31, 2024.
As context, shares outstanding were 744,121 before this resale offering and 980,664 after, assuming all registered shares are issued. PMGC also entered into an equity line structure with an initial prepaid purchase of $5,000,000, from which it received net proceeds of $3,990,000.
PMGC Holdings Inc. (ELAB) is registering under Form S-1 and discloses a diversified holding structure with subsidiaries including Northstrive Biosciences, PMGC Capital, Pacific Sun Packaging and AGA Precision Systems. Northstrive's lead asset, EL-22, is an engineered probiotic program aimed at preserving muscle during weight-loss treatment and the company cites preclinical signals such as increased anti-myostatin antibodies, reduced creatine kinase and improved motor function in mdx mice.
The filing details recent M&A: acquisitions of Pacific Sun Packaging and AGA Precision Systems, a binding term sheet with Modulant for animal-health licensing, multiple patent applications, an ATM sales agreement up to $100 million and corporate actions including reverse splits and an increase in authorized shares to 2.5 billion. Financials show operating losses and cash use that raise substantial doubt about the company's ability to continue as a going concern.